Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to increase titers to maximize productivity and elevate the performance of insulin-dependent CHO cell lines. Efficient-Pro Medium (+) Insulin is the latest addition to Thermo Fisher’s existing Efficient-Pro medium and feed system, designed to provide optimized growth and productivity for insulin-dependent CHO cell lines, with streamlined workflow and handling..

赛默飞世尔科技公司（Thermo Fisher Scientific Inc.），作为服务科学领域的全球领导者，今天推出了Gibco™ Efficient-Pro™ Medium (+) Insulin，这是一款下一代培养基，旨在提高滴度以最大化生产力，并提升依赖胰岛素的CHO细胞系的性能。Efficient-Pro Medium (+) Insulin 是赛默飞现有Efficient-Pro 培养基和补料系统中的最新产品，专为优化依赖胰岛素的CHO细胞系的生长和生产力而设计，同时简化工作流程和操作。

Designed for Biopharma Manufacturers, Biotechnology Companies, and CDMOs Focused on CHO-Based Therapeutics

专为生物制药制造商、生物技术公司和专注于CHO治疗的CDMO设计

Efficient-Pro Medium (+) Insulin offers improved protein yield and optimized productivity for insulin-dependent CHO cell lines commonly used in monoclonal antibody and biosimilar production, while also simplifying the preparation process and logistics. Biopharma manufacturers, biotechnology companies, and contract development and manufacturing organizations (CDMOs) can benefit from the following:.

Efficient-Pro Medium (+) 胰岛素为常用于单克隆抗体和生物类似物生产的胰岛素依赖型CHO细胞系提供了更高的蛋白产量和优化的生产效率，同时简化了制备流程和物流。生物制药制造商、生物技术公司以及合同开发和制造组织 (CDMO) 均可从中受益：。

For protein therapeutic developers (e.g., mAb, bispecific, Fc-fusion proteins, etc.), Efficient-Pro Medium (+) Insulin simplifies process development by providing consistent, high-performance growth and production conditions with reduced variability.

对于蛋白质治疗药物开发者（例如，单克隆抗体、双特异性抗体、Fc融合蛋白等），Efficient-Pro Medium（+）胰岛素通过提供一致的、高性能的生长和生产条件，减少了可变性，从而简化了工艺开发。

“Our announcement represents a significant enhancement in bioprocessing technology,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. “By integrating our AGT format and ensuring an AOF formulation, we are addressing key industry challenges and providing our customers with a reliable, high-performance solution.

“我们的公告代表了生物处理技术的重大进步，”赛默飞世尔科技细胞培养和细胞治疗业务副总裁兼总经理萨拉·亨内曼表示。“通过整合我们的AGT格式并确保AOF配方，我们正在应对行业关键挑战，并为客户提供可靠、高性能的解决方案。”

Efficient-Pro Medium (+) Insulin underscores our dedication to innovation and our mission to support the development of groundbreaking therapies that improve patient outcomes worldwide.”.

Efficient-Pro Medium (+) Insulin 强调了我们对创新的承诺，以及我们支持开发改善全球患者预后的突破性疗法的使命。"

Meeting the Needs of a Changing Industry

满足不断变化的行业需求

As the biologics industry pushes for faster development timelines, reduced cost-of-goods, and greater supply chain agility, Efficient-Pro Medium (+) Insulin provides a future-ready solution. It is designed to eliminate the need for manual insulin supplementation, and for robust quality systems that help support supply assurance and confidence in the delivery of consistent, high-quality products — further simplifying the bioproduction process for customers..

随着生物制品行业追求更快的开发时间表、降低商品成本以及提高供应链敏捷性，Efficient-Pro Medium (+) 胰岛素提供了一个面向未来的解决方案。它旨在消除手动添加胰岛素的需求，并通过强大的质量体系帮助支持供应保障和对持续交付高质量产品的信心，从而进一步简化客户的生物生产流程。

“With Efficient-Pro Medium (+) Insulin, we’re building on our commitment to remove barriers in bioproduction and help our customers achieve more,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “This latest innovation enables our customers to scale up rapidly, adapt to evolving project needs, and accelerate the delivery of life-changing therapies to patients.

“通过Efficient-Pro Medium (+) 胰岛素，我们正在履行消除生物生产障碍并帮助客户取得更多成果的承诺，”赛默飞世尔科技研发高级总监安迪·坎贝尔表示。“这项最新的创新使我们的客户能够快速扩大规模，适应不断变化的项目需求，并加速将改变生命的疗法交付给患者。”

Efficient-Pro Medium (+) Insulin delivers on that promise by providing the tools and support needed to streamline processes, minimize risk and bring new treatments to market faster and more efficiently than ever before.”.

Efficient-Pro Medium (+) 胰岛素通过提供简化流程、降低风险以及比以往更快更高效地将新疗法推向市场所需的工具和支持，兑现了这一承诺。

To learn more about Efficient-Pro Medium (+) Insulin, please visit the product website.

要了解有关Efficient-Pro Medium (+) Insulin的更多信息，请访问产品网站。

About Thermo Fisher Scientific

关于赛默飞世尔科技

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

赛默飞世尔科技公司是服务科学领域的全球领导者，年收入超过400亿美元。我们的使命是帮助客户使世界变得更健康、更清洁、更安全。无论我们的客户是在加速生命科学研究、解决复杂的分析难题、提高实验室生产力，还是通过诊断改善患者健康，亦或是开发和生产改变生命的疗法，我们都将全力支持他们。

Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com..

我们的全球团队通过行业领先的品牌（包括Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services、Patheon和PPD）提供无与伦比的创新技术、采购便利性和医药服务组合。欲了解更多信息，请访问www.thermofisher.com。